General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-13 | 2024-09 | 0.13 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 0.08 | 0.13 | 0.05 | 62.50% |
2024-05-09 | 2024-03 | 0.05 | 0.08 | 0.03 | 60.00% |
2024-02-28 | 2023-12 | 0.02 | 0.04 | 0.02 | 100.00% |
2023-11-08 | 2023-09 | -0.01 | 0.01 | 0.02 | 200.00% |
2023-08-09 | 2023-06 | -0.02 | -0.02 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-09 | Raymond James | Upgrade | Strong Buy | Strong Buy |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-03-26 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-07 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-02 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-18 | ELMS STEVEN A | Director | 0.00 | Sale |
2024-02-25 | FINGER ALISON CECILY | Director | 24.04K | Stock Award(Grant) |
2024-02-25 | FONG BRYANT E. | Director | 83.94K | Stock Award(Grant) |
2024-08-26 | GROSSMAN ADAM S | Chief Executive Officer | 3.78M | Sale |
2024-08-28 | GROSSMAN JERROLD B | Director | 560.01K | Sale |
2024-09-08 | GUIHEEN LAWRENCE P | Director | 154.94K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 16.37M | 60.39M | 7.28% |
2023-06-29 | Vanguard Group Inc | 12.45M | 45.92M | 5.53% |
2023-06-29 | Perceptive Advisors Llc | 11.90M | 43.91M | 5.29% |
2023-06-29 | State Street Corporation | 10.51M | 38.80M | 4.67% |
2023-06-29 | Stonepine Capital Management, LLC | 8.79M | 32.45M | 3.91% |
2023-06-29 | Nuveen Asset Management, LLC | 8.56M | 31.58M | 3.81% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 6.41M | 23.66M | 2.85% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 6.05M | 23.30M | 2.69% |
2023-08-30 | iShares Russell 2000 ETF | 4.77M | 18.35M | 2.12% |
2023-06-29 | Vanguard Extended Market Index Fund | 2.90M | 10.70M | 1.29% |
2023-06-29 | Invesco Main Street Small Cap Fund | 2.57M | 9.49M | 1.14% |
2023-06-29 | College Retirement Equities Fund-Stock Account | 2.08M | 7.68M | 0.93% |
$ADMA
In this YouTube video presentation, Julie Kim of Takeda indicated at the 8 minute mark that ADMA is involved in the manufacturing of the hyperimmune globulin therapy for COVID-19 at ADMA’s facility in Florida on behalf of the CoVIg-19 Plasma Alliance!
https://m.youtube.com/watch?v=FdA2J_7cdiw
$ADMA
Early trials of the experimental treatment indicated a 35% better chance of survival when convalescent plasma was used in "optimal patients" — which studies indicate are patients in the early stages of infection, before the virus invades the tissue and causes cell damage.
https://www.google.com/amp/s/www.cbsnews.com/amp/news/covid-convalescent-plasma-shortage/
$ADMA Phase 3 results should me announced any day now.
ADMA$ Perhaps in tonight’s JPM Healthcare Conference Takeda will provide an update on how much progress Takeda and ADMA and the Plasma Alliance have made in developing a hyperimmune globulin therapy for COVID-19.
https://www.businesswire.com/news/home/20210111005289/en/Takeda-to-Present-at-The-39th-Annual-J.P.-Morgan-Healthcare-Conference
$ADMA It’s the $1.99 special. This price won’t last long. Get it while you can.!
For comparison, other companies in the same industry with market capitalizations ranging between US$100m and US$400m had a median total CEO compensation of US$1.5m. This suggests that ADMA Biologics remunerates its CEO largely in line with the industry average. Moreover, Adam Grossman also holds US$2.1m worth of ADMA Biologics stock directly under their own name, which reveals to us that they have a significant personal stake in the company.
https://www.google.com/amp/s/simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/how-is-adma-biologics-nasdaqadma-ceo-compensated/amp
“In early 2021, we hope to have the results from that phase three clinical trial available, at which time we'll work with regulators to see how we make this most effectively available to those in need,” says Dr. Kreil.
https://www.bioprocessonline.com/doc/covid-consortium-competitive-collaboration-on-a-plasma-derived-therapy-0001
so oversold , time to buy the fear, this will go up soon
I can’t buy shares, what is happening?
History $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. $IBIO shares price in past pandemics 15$-55$, $IBIO is known for FastPharming has applications far beyond producing a COVID-19 vaccine. An example of this potential was a deal signed in October with Safi Biosolutions. The agreement will see iBio’s FastPharming system used in the bioprocessing of Safi’s blood cell therapy products. FastPharming has the potential to be part of many such deals in the future. $IBIO conference is Today (there are speculation of possible contract or partnership)
History $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. $IBIO shares price in past pandemics 15$-55$, $IBIO conference is Monday
History $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasn’t been any major viruses since 2014. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. $IBIO shares price in past pandemics 15$-55$, $IBIO conference is Monday
The core business of ADMA has been experiencing headwinds as a result of COVID-19. With a 90% effective vaccine, those headwinds will disappear. A vaccine is good news for the company.